Business
Tenaya Therapeutics to Present Preclinical Data on TN-301 HDAC6 Inhibitor at European Society of Cardiology Heart Failure 2022 Conference
Heart Failure 2022 Presentation Includes Preclinical Data Supporting TN-301 Effect in HFpEF Models TN-301 IND Submission on Track for Second Half of 2022
About this update from Tenaya Therapeutics, Inc.
[{"type":"text","content":"\nHeart Failure 2022 Presentation Includes Preclinical Data Supporting TN-301 Effect in HFpEF Models\n\nTN-301 IND Submission on Track for Second Half of 2022\n\n SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--\nTenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, announced that it will present preclinical data for its TN-301 program at the upcoming European Society of Cardiology (ESC) Heart Failure 2022 conference taking place May 21-24, 2022, in Madrid, Spain and virtually.\n\nTN-301 (previously named TYA-11631) is a small molecule HDAC6 inhibitor initially being developed by Tenaya for the potential treatment of heart failure with preserved ejection fraction (HFpEF). HFpEF is one of the greatest areas of unmet need in heart disease with more than three million patients in the United States. Data accepted for presentation at Heart Failure 2022 further elucidates the multi-modal mechanism of action by which HDAC6 inhibition has a direct impact on heart function and structure in several relevant models and compares the effect of HDAC6 inhibition to that of empagliflozin in a mouse model of HFpEF. Tenaya expects to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in the second half of 2022.\n\nDetails of the presentations are as follows:\n\nSunday, May 22, 2022\nSession: Focus on Chronic Heart Failure\nePoster Presentation: HDAC6 inhibition reduces cardiac fibrosis, enhances mitochondrial function and demonstrates comparable efficacy as empagliflozin in a mouse model of heart failure with preserved ejection fraction (Abstract 60507)\nLead Author: Jin Yang, Ph.D., Associate Director, Pharmacology, Tenaya Therapeutics\n\nTo view full event programming, please visit the ESC Heart Failure 2022 website.\n\nAbout Tenaya Therapeutics\n\nTenaya Therapeutics is a biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is developing therapies for rare genetic cardiovascular disorders, as well as for more prevalent heart conditio...